Navigation Links
Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
Date:6/23/2008

takes place every two years in Europe. In addition to world experts in the field of Cystinosis, the conference attracts Cystinosis patients and their families who want to hear the latest research in this rare lysosomal storage disease.

About Raptor Pharmaceuticals Corp.

Raptor Pharmaceuticals Corp. ("Raptor") consists of a preclinical division and a clinical division, which together form a continuous set of specialized competencies to develop Raptor's pipeline of drug product candidates from early stage to clinical stage through to commercialization. Raptor's preclinical division bioengineers novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins, while Raptor's clinical division advances clinical-stage product candidates towards marketing approval and commercialization. Raptor's initial clinical programs include the treatment of aldehyde dehydrogenase ("ALDH2") deficiency, nephropathic cystinosis and non-alcoholic steatohepatitis ("NASH").

Raptor preclinical programs target cancer, neurodegenerative disorders and infectious diseases. HepTide(TM) is designed to utilize engineered RAP-based peptides conjugated to drugs to target delivery to the liver to potentially treat primary liver cancer and hepatitis. NeuroTrans(TM) represents engineered RAP peptides created to target receptors in the brain and are currently undergoing preclinical evaluation at Stanford University for their ability to enhance the transport of therapeutics across the blood-brain barrier.

Raptor's clinical division executes the clinical development of: 1) Raptor's internally developed product candidates; 2) new chemical entities in-licensed for mid-to-late stage clinical development; 3) currently approved drugs with potential in additional indications; and 4) treatments that may be repurposed or reformulated for greater efficacy or convenience for their currently approved indications.

Rap
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
2. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
3. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
4. Raptor Pharmaceuticals Acquires Orphan Clinical Program
5. Onyx Pharmaceuticals to Present at Jefferies 2nd Annual Healthcare Conference
6. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
7. Immtech Pharmaceuticals and Beijing Capital Medical University Announce Joint Venture to Provide Contract Research Services in China
8. Synovics Pharmaceuticals Announces Continued Growth of Customer Relationships
9. GANIC Pharmaceuticals Launched with Premier Pharmaceutical Industry Executives
10. Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals
11. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 Research and Markets  has ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... http://photos.prnewswire.com/prnh/20130307/600769 ... (either DNA or RNA) into cells. This technology helps ... cells and protein metabolism by affecting the nuclear genes. ...
(Date:7/11/2014)... AZ (PRWEB) July 11, 2014 ... device company specializing in the soft tissue reconstruction ... All-Suture Anchor System for surgeries involving the shoulder ... fixation through a novel, inserter-controlled deployment method. The ... to partial deployment, anchor pull-out, or anchor displacement ...
(Date:7/10/2014)... Terascala, the industry leader in HPC ... former vice president of product management for Flexera Software, ... marketing. Terascala’s software when combined with leading compute and ... performance and most reliable solutions for processing big data. ... expansion and broaden its product portfolio. His leadership in ...
(Date:7/10/2014)... Senior supply chain management executives from over 50 ... of “Reducing Cost, Lead Time, & Defects in the ... the partnership of the Bio Supply Management Alliance ( ... SCMI) of the University of San Diego in ... Institute of Peace and Justice in San Diego, Devendra ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Terascala Expands Executive Team 2Terascala Expands Executive Team 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4
... 30 , - Shares Acquired From Biggar ... biotechnology company,focused on eye disease, vascular disease and ... based in Belgium have together acquired an 8%,stake ... Biggar Limited, a,charitable foundation that is ThromboGenics largest ...
... July 29 Osteotech, Inc.,(Nasdaq: OSTE ), a ... healing, announced today that the United States Food and ... M(TM),Biocomposite for use in spinal applications. In spinal applications, ... a bone void filler. In,March 2008, Osteotech received FDA ...
... 29 Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) ... results after the NASDAQ Global Market closes on ... Arena,s President and Chief,Executive Officer, and Robert E. ... will host a conference call at 5:00 p.m.,Eastern ...
Cached Biology Technology:ThromboGenics Announces Private Investors Acquire 8% Stake in the Company 2ThromboGenics Announces Private Investors Acquire 8% Stake in the Company 3Osteotech's Plexur M(TM) Biocomposite Receives FDA Clearance in Spine 2Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008 2Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008 3
(Date:7/11/2014)... to the hippocampus, the marginal division of the ... What is the impact degree of substance P ... memory function? Yan Yu and his team, College ... using immunofluorescence staining, that substance P receptor, neurokinin ... striatal marginal division of normal rats. Unilateral or ...
(Date:7/11/2014)... spider toxins to study the proteins that let nerve ... they have stumbled upon a biological tactic that may ... plagues in a safe and environmentally responsible way. ... lethal for one species and harmless for a closely ... specific pests without harming beneficial species like bees. A ...
(Date:7/10/2014)... June 27, 2014  Pomerantz LLP has filed ... ("Provectus" or the "Company")(NYSE-MKT: PVCT) and certain of ... States District Court, Middle District of ... of a class consisting of all persons or ... between December 17, 2013 and May 22, 2014, ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... skin and previously considered harmless, may, in fact, be the ... sinuses that strikes more than one in ten Americans each ... of California, San Francisco. The team reports this ... sinusitis may be linked to the loss of normal microbial ...
... Society of Interventional Radiology hailed the Sept. 11 ... organization that has oversight of the 24 recognized ... Radiology,s application for a new Dual Primary Certificate ... approval, ABMS and its member boards confirmed the ...
... 12, 2012 Glucocorticoids, a group of hormones that ... increase following stress. When their relationship to stress was ... cortisol prepared the body to cope with the physical ... linked to depression and other stress-related disorders, giving rise ...
Cached Biology News:Sinusitis linked to microbial diversity 2Society of Interventional Radiology hails affirmation of specialty's role in patient care 2Society of Interventional Radiology hails affirmation of specialty's role in patient care 3Society of Interventional Radiology hails affirmation of specialty's role in patient care 4Stress hormones: Good or bad for posttraumatic stress disorder risk? 2
...
... These primers are designed for sequencing ... the SP6, T7, or T3 RNA polymerase ... They are supplied at a concentration of ... functionally tested in DNA sequencing reactions using ...
BD BioCoat Collagen I 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of rat tail collagen type I....
... Mouse Antibody to Human Cytokeratin TYPE II ... (Type II) keratins. Including epidermal cell keratin ... 58kD, 65kD and 67kD. Broad keratin reactivity ... and cornea. Immunogen: ...
Biology Products: